ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Other Events
Item 8.01. Other Events.
On May 25, 2017, ADMA Biologics, Inc. (the Company) issued a
press release announcing that Adam Grossman, the President and
Chief Executive Officer of the Company, is scheduled to provide a
corporate overview at the Jefferies 2017 Healthcare Conference on
June 8, 2017 at 8:30 AM ET.
The full text of the press release is filed as Exhibit 99.1 to
this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | ADMA Biologics, Inc. Press Release, dated May 25, 2017. |
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease. ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Recent Trading Information
ADMA BIOLOGICS, INC. (NASDAQ:ADMA) closed its last trading session down -0.03 at 3.53 with 16,336 shares trading hands.
